The study used data on US veterans with type 2 diabetes, some of whom were given Ozempic or Wegovy and some more standard drugs – to measure their effect on 175 other illnesses.
There appeared to be a significant boon to heart health, with lower levels of heart attacks, stroke, heart failure and high blood pressure, in those taking the new weight-loss drugs.
They also cut the risk of substance abuse (including alcohol, opioids and cannabis) as well as reducing schizophrenia, suicidal thoughts and seizures.
Despite the study being short, and people taking the drugs for only 3.5 years because of how new they are, it reported a 12% reduction in Alzheimer’s disease.
There was also less liver cancer, muscle pain and chronic kidney disease as well as a noted reduction in bacterial infections and fever.
On the flip side, people were more likely to have problems in their digestive system. Feeling sick, tummy pain, inflammation in the stomach, diverticulitis (bulges in the intestines that can be painful) and haemorrhoids were more common on Ozempic or Wegovy.